November 1, 2009
By:Formulary journal staff
Recent FDA action (through November 2009) related to Eplivanserin, Pancrelipase, Trabectedin, Clofarabine, Fampridine-SR, Collagenase clostridium histolyticum, Oxycodone reformulated, Pegylated interferon alfa-2b, Maraviroc, Armodafinil, Relaxin, Perifosine, Glycerol phenylbutyrate, Trabedersen.
 |
October 1, 2009
By:Formulary journal staff
Recent FDA action (through October 2009) related to doxorubicin, trabectedin, carisbamate, alogliptin/pioglitazone, HPV vaccine, pralatrexate, romidepsin, hyaluronic acid, laromustine, clofarabine, prGCD, KNS-760704, rifaximin, hexvix, and quinazoline495
|
September 1, 2009
By:Formulary journal staff
Recent FDA action (through September 2009) related to cethromycin, pegloticase, guanfacine, denosumab, apaziquone, TZP-102, and beclomethasone 17,21-dipropionate
|
August 18, 2009
By:Formulary journal staff
Lilly and BioMS Medical reported that their investigational agent dirucotide did not meet the primary end point of delaying disease progression in patients with secondary progressive multiple sclerosis (SPMS) in the phase 3 MAESTRO-01 trial.
|
August 18, 2009
By:Formulary journal staff
Lundbeck and Solvay have announced that they are discontinuing development of bifeprunox for the maintenance treatment of schizophrenia.
|
August 18, 2009
By:Formulary journal staff
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has prematurely terminated a trial of sildenafil for the treatment of pulmonary arterial hypertension (PAH) in adult patients with sickle cell disease because of safety concerns.
|
August 1, 2009
By:Formulary journal staff
Recent FDA action (through August 2009) related to trazodone, casopitant, sertindole, alogliptin, bepotastine, trabectedin, and velaglucerase alfa
|
July 1, 2009
By:Formulary journal staff
Recent FDA action (through July 2009) related to bucindolol, botulinum toxin type A, rivaroxaban, quetiapine, olanzapine, ziprasidone, ofatumumab, pegloticase, pralatrexate, melphalan, and paclitaxel
|
June 1, 2009
By:Formulary journal staff
Recent FDA action (through June 2009) related to lucinactant, fenretinide, fampridine-SR, HPN-100, vitespen, and prodarsan
|
| 
Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.